DISEASE-SPECIFIC CANCER CONTROL
102 CANCER CONTROL 2015
www.prolifica.eu). Dr J Howell is supported by an NHMRC
(Australia) Early Career Fellowship. l
Dr Jessica Howell, Dr Yusuke Shimakawa, Dr Shevanthi
Nayagam, Professor Simon Taylor-Robinson and Professor Mark
Thursz are members of the PROLIFICA research team based at
Imperial College, London, UK.
References
1.easl clinical practice guidelines: Management of chronic hepatitis B virus infection. J
Hepatol. 2012;57(1):167-85.
2.parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin.
2005;55(2):74-108.
3.parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in
Indigenous Africans--burden, distribution, and trends. Lancet Oncol. 2008;9(7):683-92.
4.kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. The Gambia Liver
Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma
in West Africa. Hepatology. 2004;39(1):211-9.
5. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer
incidence and mortality worldwide: sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
6.kirk GD, Lesi OA, Mendy M, Szymanska K, Whittle H, Goedert JJ, et al. 249(ser) TP53
mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular
carcinoma. Oncogene. 2005;24(38):5858-67.
7.kuniholm MH, Lesi OA, Mendy M, Akano AO, Sam O, Hall AJ, et al. Aflatoxin exposure
and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ
Health Perspect. 2008;116(11):1553-7.
8.easl-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J
Hepatol. 2012;56(4):908-43.9.. Robotin MC, Kansil MQ, George J, Howard K, Tipper S,
Levy M, et al. Using a population-based approach to prevent hepatocellular cancer in
New South Wales, Australia: effects on health services utilisation. BMC health services
research. 2010;10:215.
10. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients
with chronic hepatitis B and advanced liver disease. The New England journal of
medicine. 2004;351(15):1521-31.
11. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management
of hepatocellular carcinoma--an updated analysis of randomized controlled trials.
Alimentary pharmacology & therapeutics. 2006;23(11):1535-47.
12. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Srinivasa K, Hutagalung Y, Bock
HL, et al. Long-term benefit of hepatitis B vaccination among children in Thailand with
transient hepatitis B virus infection who were born to hepatitis B surface antigenpositive
mothers. J Infect Dis. 2009;200(1):33-8.
13. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S,
Leyssen M, et al. Evidence of protection against clinical and chronic hepatitis B infection
20 years after infant vaccination in a high endemicity region. J Viral Hepat.
2011;18(5):369-75.
14. Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jeng-Barry A, et al.
Observational study of vaccine efficacy 24 years after the start of hepatitis B
vaccination in two Gambian villages: no need for a booster dose. PLoS One.
2013;8(3):e58029.
15. Montesano R. Hepatitis B immunization and hepatocellular carcinoma: The Gambia
Hepatitis Intervention Study. J Med Virol. 2002;67(3):444-6.
16. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national
hepatitis B immunization program in Taiwan. JAMA: the journal of the American Medical
Association. 2013;310(9):974-6.
17. Ekra D, Herbinger KH, Konate S, Leblond A, Fretz C, Cilote V, et al. A non-randomized
vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules
with a first dose at birth or age 6 weeks in Cote d'Ivoire. Vaccine. 2008;26(22):2753-61.
18. Inskip HM, Hall AJ, Chotard J, Loik F, Whittle H. Hepatitis B vaccine in the Gambian
Expanded Programme on Immunisation: factors influencing antibody response. Int J
Epidemiol 1991; 20(3): 764-9.
19. Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jeng-Barry A, et al.
Observational study of vaccine efficacy 24 years after the start of hepatitis B
vaccination in two Gambian villages: no need for a booster dose. PLoS One 2013; 8(3):
e58029.
20. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, et al. Cancer burden in
Africa and opportunities for prevention. Cancer. 2012.
21. Howell J, Lemoine M, Thursz M. Prevention of materno-foetal transmission of
hepatitis B in sub-Saharan Africa: the evidence, current practice and future challenges. J
Viral Hepat. 2014;21(6):381-96.
22. Shariff MI, Ladep NG, Cox IJ, Williams HR, Okeke E, Malu A, et al. Characterization of
urinary biomarkers of hepatocellular carcinoma using magnetic resonance
spectroscopy in a Nigerian population. J Proteome Res. 2010;9(2):1096-103.
23. Ladep NG, Dona AC, Lewis MR, Crossey MM, Lemoine M, Okeke E, et al. Discovery
and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma
(HCC) in West Africans. Hepatology. 2014.
24. Lemoine M, Shimakawa Y, Njie R, Njai HF, Nayagam S, Khalil M, et al. Food intake
increases liver stiffness measurements and hampers reliable values in patients with
chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia.
Aliment Pharmacol Ther. 2014;39(2):188-96.
25. Lemoine M, Shimakawa Y, Goldin R, Khalil M, Lloyd J, Suso P,
Nayagam S, Freeya Njai H, Taal M, Ndow G, D'Alessandro U, Njie R, Thursz M. Validation
and comparison of non-invasive markers of liver fibrosis in West African patients with
chronic hepatitis B living in The Gambia. J Hepatol 2014; 60(suppl 1): S414
26. Shimakawa Y, Bottomley C, Njie R, Mendy M. The association between maternal
hepatitis B e antigen status, as a proxy for perinatal transmission, and the risk of
hepatitis B e antigenaemia in Gambian children. BMC Public Health. 2014;14:532.Y.
Shimakawa,
27. Lemoine M, Freeya Njai H, Jatta A, Sanneh B, Taal M, Corrah MT,
D'Alessandro U, Njie R, Thursz M. Community-based screening for hepatitis B virus
infection in The Gambia, West Africa: prevalence of infection and factors affecting the
screening attendance. J Hepatol 2013; 58(Supp1): S21.
28. Lemoine M, Njai H, Shimakawa Y, Taal M, Corrah T,
D'Alessandro U, Njie R, Thursz M. Rural and urban community-based hepatitis B
screening in The Gambia: Assessment of liver disease reveals a significant proportion of
eligible patients for antiviral therapy. J Hepatol 2013; 58(suppl 1): S402
29. Shimakawa Y, Takao Y, Anderson ST, Taal M, Yamaguchi T, Giana L, et al. The
prevalence and burden of symptoms in patients with chronic liver diseases in The
Gambia, West Africa. Palliat Med. 2014.
30. Shimakawa Y, Yan HJ, Tsuchiya N, Bottomley C, Hall AJ. Association of early age at
establishment of chronic hepatitis B infection with persistent viral replication, liver
cirrhosis and hepatocellular carcinoma: a systematic review. PLoS One.
2013;8(7):e69430.
31. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology.
2009;50(3):661-2.
32. Nayagam S, Shimakawa Y, Lemoine M, Njie R, Tamba S, et al. Feasibility and cost
analysis of community based hepatitis B screening programme in Sub-Saharan Africa. J
Hepatol 2014; 60: S36.
33. Ladep NG, Dona AC, Lewis MR, Crossey MM, Lemoine M, Okeke E, et al. Discovery
and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in
West Africans. Hepatology. 2014;60(4):1291-301.
34. Xiao G, Yang J, Yan L. Comparison of Diagnostic accuracy of APRI and FIB-4 for
detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A
systemic review and meta-analysis. Hepatology. 2014.